Page 106 - Read Online

Page 10 of 10 Dolan et al. Mini-invasive Surg 2020;4:40 I http://dx.doi.org/10.20517/2574-1225.2020.17

restaging following neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB protocol #39803. J Thorac
Cardiovasc Surg 2013;146:9-16.
39. Yang CFJ, Adil SM, Anderson KL, Meyerhoff RR, Turley RR, et al. Impact of patient selection and treatment strategies on outcomes after
lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. Euro J of Cardiothorac Surg 2016;49:1607-13.
40. Yang CFJ, Meyerhoff RR, Mayne NR, Singhapricha R, Toomey CB. Long-term survival following open versus thoracoscopic lobectomy
after preoperative chemotherapy for non-small cell lung cancer. Eur J Cardiothorac Surg 2016;49:1615-23.
41. Matsuoka K, Yamada T, Matusoka T, Nagai S, Ueda M, et al. Video-assisted thoracoscopic surgery for lung cancer after induction
therapy. Asian Cardiovasc Thorac Ann 2018;26:608-14.
42. Zhang Y, Lin Q, Xu T, Deng W, Yu J, et al. Out of the darkness ad into the light: new strategies for improving treatments for locally
advanced non-small cell lung cancer. Cancer Letters 2018;421:59-62.
43. ClinicalTrials.gov. Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically
Resectable Stage III (N2) Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03871153 [Last accessed
on 18 Jun 2020]
44. ClinicalTrials.gov. NADIM II: Neo-Adjuvant Immunotherapy (NADIMII). Available from: https://clinicaltrials.gov/ct2/show/
NCT03838159 [Last accessed on 18 Jun 2020]
45. ClinicalTrials.gov. Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN). Available from:
https://clinicaltrials.gov/ct2/show/NCT03197467 [Last accessed on 18 Jun 2020]
46. ClinicalTrials.gov. Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/
ct2/show/NCT03237377 [Last accessed on 18 Jun 2020]
47. ClinicalTrials.gov. A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed
by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-
small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT04025879 [Last accessed on 18 Jun 2020]
48. ClinicalTrials.gov. Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS). Available from: https://clinicaltrials.
gov/ct2/show/NCT02994576 [Last accessed on 18 Jun 2020]
49. ClinicalTrials.gov. Neoadjuvant Nivolumab in Resectable Non-Small-Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/
show/NCT03732664 [Last accessed on 18 Jun 2020]
50. ClinicalTrials.gov. Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076).
Available from: https://clinicaltrials.gov/ct2/show/NCT02259621 [Last accessed on 18 Jun 2020]
51. ClinicalTrials.gov. Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA
Non-small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03158129 [Last accessed on 18 Jun 2020]
52. White AA, Lee DN, Mazzola E, Kucukak S, Polhemus E, et al. Adjuvant therapy following induction therapy and surgery improves
survival in N2-positive non-small cell lung cancer. Forthcoming 2020.